LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)

Summary

The purpose of the study is to test the effectiveness and safety of TTFields therapy, delivered using the NovoTTF-200T device, concomitant with pembrolizumab in subjects with metastatic NSCLC previously treated with a PD-1/PD-L1 inhibitor and platinum-based chemotherapy.

Timeline

Start

2024-10-14

Primary completion

2026-02-23

Completion

2026-02-23

Outcome

Outcome not reported

Stopped: “EF-50/LUNAR-4 was terminated because available real-world data are expected to enable Novocure to achieve the study objectives without an interventional clinical study. Termination was not due to safety concerns.”

Drugs

Indications